The year of daraxonrasib, a wearable for a myeloma drug, and more biotech news from The Readout research HHS Cancer Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout All eyes on data on Biogen’s tau therapy The year of daraxonrasib, a wearable for a…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Lots happening in London these days, my colleague Andrew Joseph reports: At a pancreatic cancer meeting, researchers were buzzing about the implications of daraxonrasib, and at a major Alzheimer’s meeting, tau therapies are taking center stage.
Back here in the U.S., HHS has begun to craft national guidance on safely tapering SSRIs, and the FDA just cleared Sanofi’s wearable injector for a myeloma drug.
Continue to STAT+ to read the full story…
US Pharma Marketing